Here, we speculate that CD206 may become a therapeutic target in bladder cancer, and clinically we can also actively detect the expression of CD206 to calculate tumor load, determine treatment responses, and observe patient prognosis (Wang et al., 2020). Here, MRC1 is linked to neoplasm.